MoneyLion Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $67.57 million. The enterprise value is -$160.01 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 84.46 million shares outstanding. The number of shares has increased by 35.16% in one year.
| Current Share Class | 84.46M |
| Shares Outstanding | 84.46M |
| Shares Change (YoY) | +35.16% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 46.21% |
| Float | 61.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.99 |
| Forward PS | 1.15 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.16
| Current Ratio | 2.16 |
| Quick Ratio | 1.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.82 |
Financial Efficiency
Return on equity (ROE) is -679.15% and return on invested capital (ROIC) is -235.59%.
| Return on Equity (ROE) | -679.15% |
| Return on Assets (ROA) | -39.55% |
| Return on Invested Capital (ROIC) | -235.59% |
| Return on Capital Employed (ROCE) | -121.74% |
| Revenue Per Employee | $214,303 |
| Profits Per Employee | -$791,019 |
| Employee Count | 310 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sutro Biopharma has paid $2.36 million in taxes.
| Income Tax | 2.36M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.61% in the last 52 weeks. The beta is 1.67, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | -75.61% |
| 50-Day Moving Average | 0.82 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 47.33 |
| Average Volume (20 Days) | 462,126 |
Short Selling Information
The latest short interest is 3.66 million, so 4.33% of the outstanding shares have been sold short.
| Short Interest | 3.66M |
| Short Previous Month | 3.66M |
| Short % of Shares Out | 4.33% |
| Short % of Float | 5.99% |
| Short Ratio (days to cover) | 3.08 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $66.43 million and -$245.22 million in losses. Loss per share was -$2.98.
| Revenue | 66.43M |
| Gross Profit | 54.82M |
| Operating Income | -229.33M |
| Pretax Income | -97.16M |
| Net Income | -245.22M |
| EBITDA | -221.98M |
| EBIT | -229.33M |
| Loss Per Share | -$2.98 |
Full Income StatementBalance Sheet
The company has $248.97 million in cash and $21.40 million in debt, giving a net cash position of $227.58 million or $2.69 per share.
| Cash & Cash Equivalents | 248.97M |
| Total Debt | 21.40M |
| Net Cash | 227.58M |
| Net Cash Per Share | $2.69 |
| Equity (Book Value) | -25.81M |
| Book Value Per Share | -0.31 |
| Working Capital | 154.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$194.68 million and capital expenditures -$3.83 million, giving a free cash flow of -$198.51 million.
| Operating Cash Flow | -194.68M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -198.51M |
| FCF Per Share | -$2.35 |
Full Cash Flow StatementMargins
| Gross Margin | 82.52% |
| Operating Margin | -345.20% |
| Pretax Margin | -365.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.16% |
| Shareholder Yield | -35.16% |
| Earnings Yield | -362.91% |
| FCF Yield | -293.79% |
Analyst Forecast
The average price target for Sutro Biopharma is $3.97, which is 396.25% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.97 |
| Price Target Difference | 396.25% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | -2.43% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sutro Biopharma has an Altman Z-Score of -4.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.89 |
| Piotroski F-Score | 1 |
